{"id":1609,"date":"2020-07-22T01:58:35","date_gmt":"2020-07-22T01:58:35","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=1609"},"modified":"2023-08-29T18:02:01","modified_gmt":"2023-08-29T18:02:01","slug":"zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=1609","title":{"rendered":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb"},"content":{"rendered":"<p>\u533b\u7528\u5927\u9ebb\u516c\u53f8<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=ZLD&amp;lang=cn\">Zelira Therapeutics (ASX: ZLD)<\/a>\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002<\/p>\n<p>PAD\u662f\u4e00\u79cd\u5faa\u73af\u72b6\u6001\uff0c\u5176\u72ed\u7a84\u7684\u52a8\u8109\u4f1a\u51cf\u5c11\u6d41\u5411\u56db\u80a2\u7684\u8840\u6db2\u3002DPN\u662f\u4e00\u79cd\u53ef\u53d1\u751f\u5728\u7cd6\u5c3f\u75c5\u60a3\u8005\u8eab\u4e0a\u7684\u795e\u7ecf\u635f\u4f24\u3002<\/p>\n<p>\u5c3d\u7ba1\u627f\u8ba4\u65b0\u5408\u540c\u7684\u5546\u4e1a\u5f71\u54cd\u8fd8\u4e3a\u65f6\u8fc7\u65e9\uff0c\u4f46Zelira\u5ba3\u79f0\u8fd9\u9879\u4ea4\u6613\u6709\u201c\u4e3a\u516c\u53f8\u521b\u9020\u672a\u6765\u957f\u671f\u6536\u5165\u6d41\u7684\u6f5c\u529b\u201d\u3002<\/p>\n<p>\u6b64\u5916\uff0cZelira\u8868\u793a\uff0c\u8be5\u4ea4\u6613\u5c06\u6709\u52a9\u4e8e\u5176\u7ee7\u7eed\u5411\u521b\u6536\u5546\u4e1a\u516c\u53f8\u7684\u65b9\u5411\u53d1\u5c55\uff0c\u901a\u8fc7\u6269\u5927\u548c\u8865\u5145\u5176\u5728\u5fc3\u8840\u7ba1\u75be\u75c5\u65b9\u9762\u7684\u6218\u7565\u5229\u76ca\uff0c\u540c\u65f6\u7ee7\u7eed\u4e13\u6ce8\u4e8e\u5728\u5168\u7403\u63a8\u51fa\u5176\u4e13\u5229\u4ea7\u54c1Zenivol\u548cHOPE\u3002<\/p>\n<p>\u4f5c\u4e3a\u534f\u8bae\u7684\u4e00\u90e8\u5206\uff0cZelira\u540c\u610f\u6388\u4e88CVSCM\u72ec\u5bb6\u6388\u6743\uff0c\u5728\u7f8e\u56fd\u751f\u4ea7\u548c\u9500\u552e\u5176\u4e13\u5229\u914d\u65b9\uff0c\u4ee5\u53ca\u6839\u636e\u8be5\u534f\u8bae\u5f00\u53d1\u7684\u6240\u6709\u672a\u6765\u4ea7\u54c1\uff0c\u8fd9\u4e9b\u4ea7\u54c1\u5c06\u57fa\u4e8e\u4ece\u5927\u9ebb\u4e2d\u63d0\u53d6\u7684\u201cCBD\u548c\u5176\u4ed6\u5927\u9ebb\u7d20\u201d\u3002<\/p>\n<p>Zelira\u8868\u793a\uff0c\u516c\u53f8\u6253\u7b97\u5229\u7528\u5176\u73b0\u6709\u7684\u4e13\u4e1a\u77e5\u8bc6\u5f00\u53d1\u4ea7\u54c1\uff0c\u63d0\u4f9b\u5177\u6709\u6f5c\u5728\u6539\u5584\u7597\u6548\u548c\u66f4\u597d\u8010\u53d7\u6027\u7684\u65b0\u4e13\u5229\u6cbb\u7597\u65b9\u6848\uff0c\u4ee5\u89e3\u51b3PAD\u53ca\u5176\u81f4\u8870\u5f31\u5e76\u53d1\u75c7\u7684\u91cd\u5927\u9700\u6c42\u3002<\/p>\n<h2>\u6761\u6b3e\u8fbe\u6210\u4e00\u81f4<\/h2>\n<p>\u6839\u636e\u534f\u8bae\uff0cZelira\u5c06\u6536\u5230\u4e00\u7b14\u4e0d\u53ef\u9000\u8fd8\u7684\u9884\u4ed8\u8bb8\u53ef\u8d39\uff0c\u4ee5\u53ca\u968f\u540e\u7684\u5546\u4e1a\u5316\u4ea7\u54c1\u7684\u7248\u7a0e\u3002<\/p>\n<p>\u4e24\u5bb6\u516c\u53f8\u90fd\u8bc1\u5b9e\uff0c\u5982\u679c\u5b83\u4eec\u80fd\u591f\u53d6\u5f97\u53d1\u5c55\u8fdb\u5c55\uff0c\u5b83\u4eec\u5c06\u5bfb\u6c42\u5728\u91cd\u8981\u7684\u5168\u7403\u5e02\u573a\u201c\u8fc5\u901f\u5546\u4e1a\u5316\u201d\u8fd9\u4e9b\u4ea7\u54c1\uff0cCVSCM\u5c06\u4fdd\u7559\u5728\u7f8e\u56fd\u7684\u72ec\u5bb6\u8425\u9500\u6743\uff0c\u800cZelira\u5c06\u4fdd\u7559\u5728\u6240\u6709\u5176\u4ed6\u5e02\u573a\u7684\u72ec\u5bb6\u8425\u9500\u6743\u3002<\/p>\n<p>\u91cd\u8981\u7684\u662f\uff0cZelira\u786e\u8ba4\u6240\u6709\u7684\u4ea7\u54c1\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6210\u672c\u5728\u7f8e\u56fd\u5c06\u7531CVSCM\u627f\u62c5\u3002<\/p>\n<p>CVSCM\u9996\u5e2d\u6267\u884c\u5b98Foluso Fakorede\u535a\u58eb\u8bf4:\u201c\u5728\u7406\u89e3\u9488\u5bf9\u591a\u79cd\u75be\u75c5\u7684\u5927\u9ebb\u7d20\u4f5c\u7528\u7684\u5206\u5b50\u673a\u5236\u65b9\u9762\u5df2\u7ecf\u53d6\u5f97\u4e86\u91cd\u5927\u8fdb\u5c55\u3002\u201d<\/p>\n<p>\u201c\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u57fa\u4e8e\u79d1\u5b66\u8bc1\u636e\u6279\u51c6\u4e86\u8bb8\u591a\u8fd9\u79cd\u57fa\u4e8e\u5927\u9ebb\u7684\u836f\u7269\u3002\u6211\u4eec\u7684\u4f7f\u547d\u662f\u4fc3\u8fdb\u6240\u6709\u60a3\u8005\u9884\u9632\u548c\u6cbb\u7597\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u5e76\u901a\u8fc7\u5b9e\u65bd\u89e3\u51b3\u672a\u6ee1\u8db3\u9700\u6c42\u7684\u5e94\u7528\u7a0b\u5e8f\uff0c\u5b9e\u73b0\u8fb9\u7f18\u793e\u533a\u7684\u5065\u5eb7\u5e73\u7b49\uff0c\u201dFakorede\u535a\u58eb\u8865\u5145\u8bf4\u3002<\/p>\n<h2>\u5bf9\u6297\u7cd6\u5c3f\u75c5<\/h2>\n<p>\u7cd6\u5c3f\u75c5\u5df2\u6210\u4e3a\u5168\u7403\u516c\u5171\u536b\u751f\u5371\u673a\uff0c\u6bcf\u5e74\u9020\u6210\u7ea63,260\u4ebf\u7f8e\u5143\u7684\u533b\u7597\u8d39\u7528\u3002<\/p>\n<p>\u6839\u636e\u7f8e\u56fd\u75be\u75c5\u63a7\u5236\u4e2d\u5fc3,\u591a\u8fbe30%\u7684\u7f8e\u56fd\u4eba\u5c06\u57282050\u5e74\u60a3\u7cd6\u5c3f\u75c5\u4e0e\u4e24\u4e2a\u8870\u5f31\u75be\u75c5\u5e76\u53d1\u75c7\u7684\u53d1\u5c55\u6240\u8c13\u7684\u201c\u52a8\u8109\u7ca5\u6837\u786c\u5316\u201d\u2014\u2014\u52a8\u8109\u5185\u6591\u5757\u7684\u7d2f\u79ef\u2014\u2014\u6700\u7ec8\u5bfc\u81f4\u66f4\u5927\u7684\u57ab\u548cDPN\u7684\u51e0\u7387\u3002<\/p>\n<p>\u6b64\u5916\uff0c\u5916\u5468\u52a8\u8109\u75be\u75c5\u662f\u5bfc\u81f4\u975e\u521b\u4f24\u6027\u622a\u80a2\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u5e76\u5f15\u53d1\u4e00\u7cfb\u5217\u5176\u4ed6\u75be\u75c5\uff0c\u8fdb\u4e00\u6b65\u964d\u4f4e\u60a3\u8005\u7684\u751f\u5b58\u80fd\u529b\uff0c\u589e\u52a0\u533b\u7597\u6210\u672c\u8d1f\u62c5\u3002<\/p>\n<p>\u5728\u76ee\u524d\u60a3\u6709\u7cd6\u5c3f\u75c5\u76843000\u4e07\u7f8e\u56fd\u4eba\u4e2d\uff0c50\u5c81\u4ee5\u4e0a\u7684\u4eba\u4e2d\u6709\u4e09\u5206\u4e4b\u4e00\u53ef\u80fd\u60a3\u5916\u5468\u52a8\u8109\u75be\u75c5\u3002<\/p>\n<p>\u6839\u636e2016\u5e74\u53d1\u5e03\u7684\u4e00\u9879\u5168\u7403\u75be\u75c5\u8d1f\u62c5\u8c03\u67e5\uff0c\u5168\u7403\u5916\u5468\u52a8\u8109\u75be\u75c5\u7684\u60a3\u75c5\u7387\u4f30\u8ba1\u4e3a2\u4ebf\u3002<\/p>\n<p>Zelira\u9996\u5e2d\u6267\u884c\u5b98\u517c\u8463\u4e8b\u603b\u7ecf\u7406Oludare Odumosu\u535a\u58eb\u8bf4:\u201c\u6211\u4eec\u4e0eCVSCM\u7684\u5408\u4f5c\u5173\u7cfb\u7b26\u5408\u6211\u4eec\u7684\u76ee\u6807\u9002\u5e94\u75c7\uff0c\u5373\u4ee5\u5927\u9ebb\u4e3a\u57fa\u7840\u7684\u836f\u7269\u53ef\u4ee5\u4f5c\u4e3a\u5b89\u5168\u3001\u6709\u6548\u548c\u53ef\u83b7\u5f97\u7684\u9009\u62e9\u3002\u201d<\/p>\n<p>\u201c\u8fd9\u662f\u8be5\u9886\u57df\u7684\u9996\u6b21\u5408\u4f5c\uff0c\u4f7f\u6211\u4eec\u80fd\u591f\u5173\u6ce8\u5916\u5468\u52a8\u8109\u75be\u75c5\u5bf9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u7684\u5f71\u54cd\u3002Zelira\u5f88\u8363\u5e78\u80fd\u5c06\u6211\u4eec\u79d1\u5b66\u7684\u4ea7\u54c1\u5f00\u53d1\u4e13\u4e1a\u77e5\u8bc6\u7528\u4e8e\u8fd9\u4e00\u5c1a\u672a\u6ee1\u8db3\u7684\u9700\u6c42\uff0c\u5e76\u5c06\u6211\u4eec\u7684\u89e6\u89d2\u4f38\u5165\u65b0\u7684\u5e02\u573a\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002 PAD\u662f\u4e00\u79cd\u5faa\u73af\u72b6\u6001\uff0c\u5176\u72ed\u7a84\u7684\u52a8\u8109\u4f1a\u51cf\u5c11\u6d41\u5411\u56db\u80a2\u7684\u8840\u6db2\u3002DPN\u662f\u4e00\u79cd\u53ef\u53d1\u751f\u5728\u7cd6\u5c3f\u75c5\u60a3\u8005\u8eab\u4e0a\u7684\u795e\u7ecf\u635f\u4f24\u3002 \u5c3d\u7ba1\u627f\u8ba4\u65b0\u5408\u540c\u7684\u5546\u4e1a\u5f71\u54cd\u8fd8\u4e3a\u65f6\u8fc7\u65e9\uff0c\u4f46Zelira\u5ba3\u79f0\u8fd9\u9879\u4ea4\u6613\u6709\u201c\u4e3a\u516c\u53f8\u521b\u9020\u672a\u6765\u957f\u671f\u6536\u5165\u6d41\u7684\u6f5c\u529b\u201d\u3002 \u6b64\u5916\uff0cZelira\u8868\u793a\uff0c\u8be5\u4ea4\u6613\u5c06\u6709\u52a9\u4e8e\u5176\u7ee7\u7eed\u5411\u521b\u6536\u5546\u4e1a\u516c\u53f8\u7684\u65b9\u5411\u53d1\u5c55\uff0c\u901a\u8fc7\u6269\u5927\u548c\u8865\u5145\u5176\u5728\u5fc3\u8840\u7ba1\u75be\u75c5\u65b9\u9762\u7684\u6218\u7565\u5229\u76ca\uff0c\u540c\u65f6\u7ee7\u7eed\u4e13\u6ce8\u4e8e\u5728\u5168\u7403\u63a8\u51fa\u5176\u4e13\u5229\u4ea7\u54c1Zenivol\u548cHOPE\u3002 \u4f5c\u4e3a\u534f\u8bae\u7684\u4e00\u90e8\u5206\uff0cZelira\u540c\u610f\u6388\u4e88CVSCM\u72ec\u5bb6\u6388\u6743\uff0c\u5728\u7f8e\u56fd\u751f\u4ea7\u548c\u9500\u552e\u5176\u4e13\u5229\u914d\u65b9\uff0c\u4ee5\u53ca\u6839\u636e\u8be5\u534f\u8bae\u5f00\u53d1\u7684\u6240\u6709\u672a\u6765\u4ea7\u54c1\uff0c\u8fd9\u4e9b\u4ea7\u54c1\u5c06\u57fa\u4e8e\u4ece\u5927\u9ebb\u4e2d\u63d0\u53d6\u7684\u201cCBD\u548c\u5176\u4ed6\u5927\u9ebb\u7d20\u201d\u3002 Zelira\u8868\u793a\uff0c\u516c\u53f8\u6253\u7b97\u5229\u7528\u5176\u73b0\u6709\u7684\u4e13\u4e1a\u77e5\u8bc6\u5f00\u53d1\u4ea7\u54c1\uff0c\u63d0\u4f9b\u5177\u6709\u6f5c\u5728\u6539\u5584\u7597\u6548\u548c\u66f4\u597d\u8010\u53d7\u6027\u7684\u65b0\u4e13\u5229\u6cbb\u7597\u65b9\u6848\uff0c\u4ee5\u89e3\u51b3PAD\u53ca\u5176\u81f4\u8870\u5f31\u5e76\u53d1\u75c7\u7684\u91cd\u5927\u9700\u6c42\u3002 \u6761\u6b3e\u8fbe\u6210\u4e00\u81f4 \u6839\u636e\u534f\u8bae\uff0cZelira\u5c06\u6536\u5230\u4e00\u7b14\u4e0d\u53ef\u9000\u8fd8\u7684\u9884\u4ed8\u8bb8\u53ef\u8d39\uff0c\u4ee5\u53ca\u968f\u540e\u7684\u5546\u4e1a\u5316\u4ea7\u54c1\u7684\u7248\u7a0e\u3002 \u4e24\u5bb6\u516c\u53f8\u90fd\u8bc1\u5b9e\uff0c\u5982\u679c\u5b83\u4eec\u80fd\u591f\u53d6\u5f97\u53d1\u5c55\u8fdb\u5c55\uff0c\u5b83\u4eec\u5c06\u5bfb\u6c42\u5728\u91cd\u8981\u7684\u5168\u7403\u5e02\u573a\u201c\u8fc5\u901f\u5546\u4e1a\u5316\u201d\u8fd9\u4e9b\u4ea7\u54c1\uff0cCVSCM\u5c06\u4fdd\u7559\u5728\u7f8e\u56fd\u7684\u72ec\u5bb6\u8425\u9500\u6743\uff0c\u800cZelira\u5c06\u4fdd\u7559\u5728\u6240\u6709\u5176\u4ed6\u5e02\u573a\u7684\u72ec\u5bb6\u8425\u9500\u6743\u3002 \u91cd\u8981\u7684\u662f\uff0cZelira\u786e\u8ba4\u6240\u6709\u7684\u4ea7\u54c1\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6210\u672c\u5728\u7f8e\u56fd\u5c06\u7531CVSCM\u627f\u62c5\u3002 CVSCM\u9996\u5e2d\u6267\u884c\u5b98Foluso Fakorede\u535a\u58eb\u8bf4:\u201c\u5728\u7406\u89e3\u9488\u5bf9\u591a\u79cd\u75be\u75c5\u7684\u5927\u9ebb\u7d20\u4f5c\u7528\u7684\u5206\u5b50\u673a\u5236\u65b9\u9762\u5df2\u7ecf\u53d6\u5f97\u4e86\u91cd\u5927\u8fdb\u5c55\u3002\u201d \u201c\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u57fa\u4e8e\u79d1\u5b66\u8bc1\u636e\u6279\u51c6\u4e86\u8bb8\u591a\u8fd9\u79cd\u57fa\u4e8e\u5927\u9ebb\u7684\u836f\u7269\u3002\u6211\u4eec\u7684\u4f7f\u547d\u662f\u4fc3\u8fdb\u6240\u6709\u60a3\u8005\u9884\u9632\u548c\u6cbb\u7597\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u5e76\u901a\u8fc7\u5b9e\u65bd\u89e3\u51b3\u672a\u6ee1\u8db3\u9700\u6c42\u7684\u5e94\u7528\u7a0b\u5e8f\uff0c\u5b9e\u73b0\u8fb9\u7f18\u793e\u533a\u7684\u5065\u5eb7\u5e73\u7b49\uff0c\u201dFakorede\u535a\u58eb\u8865\u5145\u8bf4\u3002 \u5bf9\u6297\u7cd6\u5c3f\u75c5 \u7cd6\u5c3f\u75c5\u5df2\u6210\u4e3a\u5168\u7403\u516c\u5171\u536b\u751f\u5371\u673a\uff0c\u6bcf\u5e74\u9020\u6210\u7ea63,260\u4ebf\u7f8e\u5143\u7684\u533b\u7597\u8d39\u7528\u3002 \u6839\u636e\u7f8e\u56fd\u75be\u75c5\u63a7\u5236\u4e2d\u5fc3,\u591a\u8fbe30%\u7684\u7f8e\u56fd\u4eba\u5c06\u57282050\u5e74\u60a3\u7cd6\u5c3f\u75c5\u4e0e\u4e24\u4e2a\u8870\u5f31\u75be\u75c5\u5e76\u53d1\u75c7\u7684\u53d1\u5c55\u6240\u8c13\u7684\u201c\u52a8\u8109\u7ca5\u6837\u786c\u5316\u201d\u2014\u2014\u52a8\u8109\u5185\u6591\u5757\u7684\u7d2f\u79ef\u2014\u2014\u6700\u7ec8\u5bfc\u81f4\u66f4\u5927\u7684\u57ab\u548cDPN\u7684\u51e0\u7387\u3002 \u6b64\u5916\uff0c\u5916\u5468\u52a8\u8109\u75be\u75c5\u662f\u5bfc\u81f4\u975e\u521b\u4f24\u6027\u622a\u80a2\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u5e76\u5f15\u53d1\u4e00\u7cfb\u5217\u5176\u4ed6\u75be\u75c5\uff0c\u8fdb\u4e00\u6b65\u964d\u4f4e\u60a3\u8005\u7684\u751f\u5b58\u80fd\u529b\uff0c\u589e\u52a0\u533b\u7597\u6210\u672c\u8d1f\u62c5\u3002 \u5728\u76ee\u524d\u60a3\u6709\u7cd6\u5c3f\u75c5\u76843000\u4e07\u7f8e\u56fd\u4eba\u4e2d\uff0c50\u5c81\u4ee5\u4e0a\u7684\u4eba\u4e2d\u6709\u4e09\u5206\u4e4b\u4e00\u53ef\u80fd\u60a3\u5916\u5468\u52a8\u8109\u75be\u75c5\u3002 \u6839\u636e2016\u5e74\u53d1\u5e03\u7684\u4e00\u9879\u5168\u7403\u75be\u75c5\u8d1f\u62c5\u8c03\u67e5\uff0c\u5168\u7403\u5916\u5468\u52a8\u8109\u75be\u75c5\u7684\u60a3\u75c5\u7387\u4f30\u8ba1\u4e3a2\u4ebf\u3002 Zelira\u9996\u5e2d\u6267\u884c\u5b98\u517c\u8463\u4e8b\u603b\u7ecf\u7406Oludare Odumosu\u535a\u58eb\u8bf4:\u201c\u6211\u4eec\u4e0eCVSCM\u7684\u5408\u4f5c\u5173\u7cfb\u7b26\u5408\u6211\u4eec\u7684\u76ee\u6807\u9002\u5e94\u75c7\uff0c\u5373\u4ee5\u5927\u9ebb\u4e3a\u57fa\u7840\u7684\u836f\u7269\u53ef\u4ee5\u4f5c\u4e3a\u5b89\u5168\u3001\u6709\u6548\u548c\u53ef\u83b7\u5f97\u7684\u9009\u62e9\u3002\u201d \u201c\u8fd9\u662f\u8be5\u9886\u57df\u7684\u9996\u6b21\u5408\u4f5c\uff0c\u4f7f\u6211\u4eec\u80fd\u591f\u5173\u6ce8\u5916\u5468\u52a8\u8109\u75be\u75c5\u5bf9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u7684\u5f71\u54cd\u3002Zelira\u5f88\u8363\u5e78\u80fd\u5c06\u6211\u4eec\u79d1\u5b66\u7684\u4ea7\u54c1\u5f00\u53d1\u4e13\u4e1a\u77e5\u8bc6\u7528\u4e8e\u8fd9\u4e00\u5c1a\u672a\u6ee1\u8db3\u7684\u9700\u6c42\uff0c\u5e76\u5c06\u6211\u4eec\u7684\u89e6\u89d2\u4f38\u5165\u65b0\u7684\u5e02\u573a\u3002<\/p>\n","protected":false},"author":5,"featured_media":8716,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[101],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb<\/title>\n<meta name=\"description\" content=\"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb\" \/>\n<meta property=\"og:description\" content=\"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-22T01:58:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Zelira-Therapeutics-ASX-ZLD-Peripheral-Arterial-Disease-Diabetic-Neuropathies.jpg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb\" \/>\n<meta name=\"twitter:description\" content=\"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Zelira-Therapeutics-ASX-ZLD-Peripheral-Arterial-Disease-Diabetic-Neuropathies.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/\",\"name\":\"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-07-22T01:58:35+00:00\",\"dateModified\":\"2023-08-29T18:02:01+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb","description":"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb","og_description":"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/","og_site_name":"smallcapsCN","article_published_time":"2020-07-22T01:58:35+00:00","article_modified_time":"2023-08-29T18:02:01+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Zelira-Therapeutics-ASX-ZLD-Peripheral-Arterial-Disease-Diabetic-Neuropathies.jpg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_title":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb","twitter_description":"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Zelira-Therapeutics-ASX-ZLD-Peripheral-Arterial-Disease-Diabetic-Neuropathies.jpg","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/","url":"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/","name":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-07-22T01:58:35+00:00","dateModified":"2023-08-29T18:02:01+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u533b\u7528\u5927\u9ebb\u516c\u53f8Zelira Therapeutics (ASX: ZLD)\u5df2\u627f\u8bfa\u4e0eCardiovascular Solutions of Central Mississippi (CVSCM)\u7b7e\u7f72\u4e00\u9879\u5177\u6709\u7ea6\u675f\u529b\u7684\u4e94\u5e74\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u5916\u5468\u52a8\u8109\u75be\u75c5(PAD)\u548c\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8(DPN)\u76f8\u5173\u75c7\u72b6\u7684\u4ea7\u54c1\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/zelira-therapeutics-targets-arterial-disease-diabetic-illnesses-medicinal-cannabis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Zelira Therapeutics\u7684\u76ee\u6807\u662f\u52a8\u8109\u75be\u75c5\u548c\u7cd6\u5c3f\u75c5\u75be\u75c5\u7684\u836f\u7528\u5927\u9ebb"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1609"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1609"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1609\/revisions"}],"predecessor-version":[{"id":8715,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1609\/revisions\/8715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/8716"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}